Calamos Advisors’s DexCom DXCM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $6.41M | Sell |
95,248
-1,771
| -2% | -$118K | 0.02% | 516 |
|
|
2026
Q1 | $6.09M | Hold |
97,019
| – | – | 0.02% | 517 |
|
|
2025
Q4 | $6.44M | Sell |
97,019
-3,940
| -4% | -$255K | 0.02% | 490 |
|
|
2025
Q3 | $6.79M | Hold |
100,959
| – | – | 0.03% | 501 |
|
|
2025
Q2 | $8.81M | Hold |
100,959
| – | – | 0.03% | 436 |
|
|
2025
Q1 | $6.89M | Sell |
100,959
-74,548
| -42% | -$6.08M | 0.03% | 465 |
|
|
2024
Q4 | $13.6M | Buy |
175,507
+411
| +0.2% | +$30.4K | 0.06% | 338 |
|
|
2024
Q3 | $11.7M | Sell |
175,096
-150,829
| -46% | -$12.4M | 0.05% | 372 |
|
|
2024
Q2 | $37M | Buy |
325,925
+42,050
| +15% | +$5.32M | 0.16% | 143 |
|
|
2024
Q1 | $39.4M | Buy |
283,875
+9,012
| +3% | +$1.13M | 0.19% | 142 |
|
|
2023
Q4 | $34.1M | Sell |
274,863
-15,932
| -5% | -$1.63M | 0.17% | 168 |
|
|
2023
Q3 | $27.1M | Buy |
290,795
+370
| +0.1% | +$41.7K | 0.14% | 186 |
|
|
2023
Q2 | $37.3M | Buy |
290,425
+35,766
| +14% | +$4.33M | 0.18% | 144 |
|
|
2023
Q1 | $29.6M | Sell |
254,659
-14,207
| -5% | -$1.59M | 0.14% | 176 |
|
|
2022
Q4 | $30.4M | Buy |
268,866
+123,607
| +85% | +$13.6M | 0.14% | 186 |
|
|
2022
Q3 | $11.7M | Buy |
145,259
+29,295
| +25% | +$2.48M | 0.05% | 424 |
|
|
2022
Q2 | $8.64M | Sell |
115,964
-87,064
| -43% | -$7.95M | 0.04% | 543 |
|
|
2022
Q1 | $26M | Buy |
203,028
+27,260
| +16% | +$2.98M | 0.1% | 240 |
|
|
2021
Q4 | $23.6M | Sell |
175,768
-4,096
| -2% | -$589K | 0.09% | 244 |
|
|
2021
Q3 | $24.6M | Sell |
179,864
-14,096
| -7% | -$1.78M | 0.11% | 217 |
|
|
2021
Q2 | $20.7M | Sell |
193,960
-544
| -0.3% | -$52.2K | 0.09% | 244 |
|
|
2021
Q1 | $17.5M | Buy |
194,504
+42,448
| +28% | +$3.98M | 0.1% | 229 |
|
|
2020
Q4 | $14.1M | Sell |
152,056
-48
| -0% | -$4.29K | 0.08% | 264 |
|
|
2020
Q3 | $15.7M | Buy |
152,104
+141,876
| +1,387% | +$14.8M | 0.1% | 220 |
|
|
2020
Q2 | $1.04M | Buy |
10,228
+6,416
| +168% | +$574K | 0.01% | 635 |
|
|
2020
Q1 | $257K | Sell |
3,812
-88
| -2% | -$5.48K | ﹤0.01% | 677 |
|
|
2019
Q4 | $213K | Sell |
3,900
-2,208
| -36% | -$105K | ﹤0.01% | 754 |
|
|
2019
Q3 | $228K | Buy |
+6,108
| New | +$237K | ﹤0.01% | 735 |
|
|
2019
Q2 | – | Sell |
-8,240
| Closed | -$245K | – | 745 |
|
|
2019
Q1 | $245K | Buy |
8,240
+240
| +3% | +$8.43K | ﹤0.01% | 638 |
|
|
2018
Q4 | $240K | Buy |
+8,000
| New | +$254K | ﹤0.01% | 647 |
|
|
2016
Q4 | – | Sell |
-836,320
| Closed | -$18.3M | – | 638 |
|
|
2016
Q3 | $18.3M | Sell |
836,320
-311,480
| -27% | -$6.93M | 0.13% | 200 |
|
|
2016
Q2 | $22.8M | Buy |
+1,147,800
| New | +$19.5M | 0.16% | 190 |
|
|
2013
Q3 | – | Sell |
-59,200
| Closed | -$332K | – | 603 |
|
|
2013
Q2 | $332K | Buy |
+59,200
| New | +$284K | ﹤0.01% | 558 |
|
Other funds holding DXCM
DCP
SIMG
Calamos Advisors's DXCM Position: Q2 2026 in Review
Calamos Advisors reduced its DexCom (DXCM) stake by 1.8% in Q2 2026, selling an estimated $118K and leaving 95,248 shares worth $6.41M. The position accounts for 0.02% of the portfolio, ranked #516.
Calamos Advisors first reported a position in DXCM in Q2 2013 and has held it in 33 quarters since. The position peaked at $39.4M in Q1 2024. 496 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.
- Calamos Advisors held 95,248 shares of DexCom worth $6.41M as of Q2 2026.
- Calamos Advisors sold 1,771 DexCom shares in Q2 2026, an estimated $118K.
- DexCom made up 0.02% of Calamos Advisors's portfolio in Q2 2026, its #516 holding.
- Calamos Advisors first reported a position in DexCom in Q2 2013 and has held it in 33 quarters since.
- Calamos Advisors's DexCom position peaked at $39.4M in Q1 2024.
- 496 funds tracked by Wall St. Rank held DexCom as of Q2 2026.
Based on Calamos Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.